Digestive Health & Gastroenterology Clinical Trials Update: Week 32, 2026

Published August 7, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

Optimizing H. Pylori Eradication Regimen Under Intensified Acid Suppression

This Phase 4 study from Qilu Hospital of Shandong University is exploring a new approach to treat Helicobacter pylori infection by using stronger acid suppression. The goal is to create a shorter and simpler treatment that patients can follow more easily while still effectively clearing the infection. If successful, this could make managing H. pylori infections less burdensome and improve outcomes for adults worldwide.

Phase 3 Study to Evaluate the Safety and Efficacy of Hydrocortisone Acetate Suppositories

This recently completed Phase 3 trial tested hydrocortisone acetate suppositories in adults with ulcerative proctitis, a condition causing inflammation in the rectum. The study compared once or twice daily dosing to placebo to see if it helps relieve symptoms safely. The findings may provide a more convenient treatment option for patients dealing with this form of ulcerative colitis.

Efficacy and Safety of Weifuchun Tablet in Reversing Gastric Intestinal Metaplasia

This ongoing Phase 4 trial in China is investigating whether Weifuchun tablets can reverse gastric intestinal metaplasia, a precancerous condition of the stomach lining. The study focuses on adults without H. pylori infection and involves daily treatment for six months. Positive results could offer a new way to reduce the risk of stomach cancer in affected patients.

Trimebutine Maleate for Enhancing Gastric Visualization in Acute Upper Gastrointestinal Bleeding

Assiut University is conducting a Phase 2 trial testing Trimebutine Maleate to improve stomach visibility during emergency endoscopy for adults experiencing acute upper gastrointestinal bleeding. Better visualization may help doctors identify bleeding sites more quickly and provide timely treatment. This could enhance care during urgent situations involving gastrointestinal hemorrhage.

Pilot and Feasibility Study of 2'-FL as a Dietary Supplement in IBD Patients Receiving Stable Maintenance Anti-TNF Therapy

This Phase 1 study evaluated the safety and potential benefits of a dietary supplement called 2'-FL in children and young adults with inflammatory bowel diseases who are stable on anti-TNF medications. The research looked at effects on gut bacteria and symptoms while patients were in remission. The results may support new complementary options to maintain gut health in these patients.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.